← Leaderboards
Karen Hsieh Lu
University Of Texas Md Anderson Can Ctr
$10,934,889
Attributed
$14,471,550
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$38,724,771 · 10
By mechanism
P50$31,810,589 · 5
T32$5,841,335 · 1
N01$902,847 · 1
P30$98,959 · 1
R13$71,041 · 2
Top collaborators
- Anil K Sood13 shared
- Russell R Broaddus11 shared
- Diane Bodurka5 shared
- Michael Frumovitz3 shared
- Immaculata Devivo1 shared
- Sara H Olson1 shared
- Veronica Wendy Setiawan1 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
Others in their field
Top investigators on “Uterine Cancer”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- Philip J Disaia · University Of California Irvine$51,502,747
- Larry Arthur$19,201,027
- Steven D Leach · Dartmouth College$17,616,467
- Ie-Ming Shih · Johns Hopkins University$11,043,157
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$10,055,704
Research focus
Uterine CancerPreventionInnovationEndometrial CarcinomaRecurrenceWomanGynecologicHigh RiskProgramsBaseTranslational ResearchClinical TrialsMalignant NeoplasmsMolecularObesityBiological MarkersBasic ScienceResearch PersonnelAnticancer ResearchNovel StrategiesMalignant Female Reproductive System NeoplasmCancer CenterNovel TherapeuticsPathology
Grant awards (68)
Training of Academic Gynecologic Oncologists$561,727
T32 · FY2023 · CA · contact PI
08 Gynecological Cancers$18,707
P30 · FY2023 · CA · contact PI
Training of Academic Gynecologic Oncologists$547,824
T32 · FY2022 · CA · contact PI
08 Gynecological Cancers$18,707
P30 · FY2022 · CA · contact PI
Training of Academic Gynecologic Oncologists$471,936
T32 · FY2021 · CA · contact PI
08 Gynecological Cancers$18,707
P30 · FY2021 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$1,986,436
P50 · FY2020 · CA · contact PI
Training of Academic Gynecologic Oncologists$475,582
T32 · FY2020 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$302,816
P50 · FY2020 · CA · contact PI
Administrative Core$274,930
P50 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$214,963
P50 · FY2020 · CA · contact PI
Evaluation of siRNA nanoformulations and aerosol delivery for treatment of SARS-CoV-2$162,000
P50 · FY2020 · CA · contact PI
08 Gynecological Cancers$18,675
P30 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$10,000
P50 · FY2020 · CA · contact PI
Administrative Core$4,007
P50 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,090,228
P50 · FY2019 · CA · contact PI
Training of Academic Gynecologic Oncologists$437,175
T32 · FY2019 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$290,154
P50 · FY2019 · CA · contact PI
Administrative Core$263,434
P50 · FY2019 · CA · contact PI
08 Gynecological Cancers$18,707
P30 · FY2019 · CA · contact PI
08 Gynecological Cancers$5,456
P30 · FY2019 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,268,692
P50 · FY2018 · CA · contact PI
Training of Academic Gynecologic Oncologists$467,856
T32 · FY2018 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$291,695
P50 · FY2018 · CA · contact PI
Administrative Core$262,959
P50 · FY2018 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$192,000
P50 · FY2018 · CA · contact PI
Administrative Core$17,456
P50 · FY2018 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$17,454
P50 · FY2018 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,299,997
P50 · FY2017 · CA · contact PI
Training of Academic Gynecologic Oncologists$468,471
T32 · FY2017 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$311,994
P50 · FY2017 · CA · contact PI
Administrative Core$283,265
P50 · FY2017 · CA · contact PI
Revision: MD Anderson Gynecologic SPORE for Uterine Cancers$192,000
P50 · FY2017 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,162,000
P50 · FY2016 · CA · contact PI
Training of Academic Gynecologic Oncologists$466,239
T32 · FY2016 · CA · contact PI
P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer$295,325
P50 · FY2016 · CA · contact PI
Administrative Core$253,930
P50 · FY2016 · CA · contact PI
Training of Academic Gynecologic Oncologists$401,193
T32 · FY2015 · CA
M.D. Anderson Gynecologic SPORE for Uterine Cancers$2,162,000
P50 · FY2014 · CA · contact PI
Metformin for the Chemoprevention of Endometrial Cancer In Obese, Insulin-Resista$921,220
P50 · FY2014 · CA · contact PI
Training of Academic Gynecologic Oncologists$407,137
T32 · FY2014 · CA
Administrative Core$117,389
P50 · FY2014 · CA · contact PI
Advances in Endometrial Cancer Epidemiology and Biology$31,100
R13 · FY2014 · CA
M.D. Anderson Gynecologic SPORE for Uterine Cancers$1,418,231
P50 · FY2013 · CA · contact PI
Training of Academic Gynecologic Oncologists$392,980
T32 · FY2013 · CA
Metformin for the Chemoprevention of Endometrial Cancer In Obese, Insulin-Resista$259,658
P50 · FY2013 · CA · contact PI
Administrative Core$187,791
P50 · FY2013 · CA · contact PI
M.D. Anderson Gynecologic SPORE for Uterine Cancers$2,300,000
P50 · FY2012 · CA · contact PI
Metformin for the Chemoprevention of Endometrial Cancer In Obese, Insulin-Resista$961,601
P50 · FY2012 · CA · contact PI
Training of Academic Gynecologic Oncologists$391,105
T32 · FY2012 · CA
Administrative Core$126,197
P50 · FY2012 · CA · contact PI
M.D. Anderson Gynecologic SPORE for Uterine Cancers$2,185,000
P50 · FY2011 · CA · contact PI
Metformin for the Chemoprevention of Endometrial Cancer In Obese, Insulin-Resista$901,649
P50 · FY2011 · CA · contact PI
Training of Academic Gynecologic Oncologists$352,110
T32 · FY2011 · CA
Administrative Core$118,122
P50 · FY2011 · CA · contact PI
M.D. Anderson Gynecologic SPORE for Uterine Cancers$2,300,000
P50 · FY2010 · CA · contact PI
Metformin for the Chemoprevention of Endometrial Cancer In Obese, Insulin-Resista$972,872
P50 · FY2010 · CA · contact PI
Administrative Core$121,450
P50 · FY2010 · CA · contact PI
Annual Uterine Cancer Biology Symposium$10,000
R13 · FY2010 · CA · contact PI
MD Anderson Cancer Ctr. Gynecology SPORE: Uterine Cancer$461,935
P50 · FY2009 · CA · contact PI
Annual Uterine Cancer Symposium$971
R13 · FY2008 · CA · contact PI
MD Anderson Cancer Ctr. Gynecology SPORE: Uterine Cancer$1,847,739
P50 · FY2007 · CA · contact PI
Annual Uterine Cancer Symposium$5,971
R13 · FY2007 · CA · contact PI
Annual Uterine Cancer Symposium$6,000
R13 · FY2006 · CA · contact PI
PHASE II CLINICAL TRAIL - AN EXPLORATORY STUDY TO IDENTIFY POTENTIAL S-261005127$0
N01 · FY2006 · CN · contact PI
Annual Uterine Cancer Symposium$6,000
R13 · FY2005 · CA
Annual Uterine Cancer Symposium$10,999
R13 · FY2004 · CA
PHASE II CLINICAL TRAIL - AN EXPLORATORY STUDY TO IDENTI$902,847
N01 · FY2000 · CN